Jonathan Rubin
Chief Tech/Sci/R&D Officer chez SUPERNUS PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jack Khattar | M | 62 | 19 ans | |
Charles Newhall | M | 79 | 19 ans | |
Georges Gemayel | M | 64 | 9 ans | |
John Siebert | M | 84 | 13 ans | |
Frederick Hudson | M | 78 | 14 ans | |
Carrolee Barlow | M | 60 | 6 ans | |
Padmanabh P. Bhatt | M | 66 | 19 ans | |
Frank Mottola | M | 52 | 19 ans | |
Bethany Sensenig | F | 48 | 1 ans | |
Timothy Dec | M | 66 | 3 ans | |
Kevin T. Anderson | M | 61 | 12 ans | |
Bryan A. Roecklein | M | - | 9 ans | |
Todd Horich | M | - | 6 ans | |
Taylor Raiford | M | - | 9 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Udi Gilboa | M | 57 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 6 ans |
David Baker | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 ans |
Yuval Yanai | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 1 ans |
Joao Siffert | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Arieh Ben-Yosef | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 ans |
Tomer Berkovitz | M | 44 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 ans |
Amir Efrati | M | 50 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Tami Martin | F | 68 | 16 ans | |
James Kelly | M | 58 | 1 ans | |
Stefan Schwabe | M | 72 | 8 ans | |
Hagit Marchaim | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Orli Tori | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 17 | 65,38% |
Israël | 9 | 34,62% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jonathan Rubin
- Réseau Personnel